Within FDA, an Office of Orphan Products Development has overseen the development and marketing of more than 400 rare disease drugs and biologic products since 1983. In October 2013, FDA awarded 15 grants totaling about $15 million to foster treatments for such rare conditions as Stargardt disease, an inherited form of juvenile macular degeneration ($167,000 to Alkeus Pharmaceuticals, Boston) and to treat and prevent porphyria attacks ($1.5 million to UTMB).